Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41 - Wikidata - awgldk - TriplyDB

Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41

Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41

http://www.wikidata.org/entity/Q24681784

about

Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1 Serologic reactivity of a synthetic peptide from human immunodeficiency virus type 1 gp41 with sera from a Mexican population Heat shock protein 70 is a potent activator of the human complement system.Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1.

P2860

Q24541449-DFDC402C-B5F5-462E-A496-BEC771C786EF Q35228003-4A646C34-F285-4FA4-BBEA-F5B7A462E86B Q37489832-41F4CD4D-DA18-4595-9C61-9A1A40455FF4 Q39810120-388EAA5F-ECDD-486E-B3ED-9590BBB6CE74

P2860

Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41

http://www.wikidata.org/entity/Q24681784

description

1993 nî lūn-bûn

@nan

1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@ast

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@en

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@nl

type

label

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@ast

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@en

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@nl

prefLabel

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@ast

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@en

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@nl

P1433

Q24681784-EFCC5AF2-239B-4410-881F-6C00AEB3A4D3

P1476

Q24681784-99AB0E75-FAD2-4083-8ED4-9083BD55A708

P2093

Q24681784-0AA6FF05-7AE2-47C2-8313-2CF896724551

Q24681784-246294BE-1E77-40FE-8F10-D88CD5DA941D

Q24681784-5E5FD4F6-2CE3-4DAB-91B7-4D1503DF2993

Q24681784-605F4AE0-8861-4922-A7B7-645006245AF6

Q24681784-6F3321EF-E5C8-4064-8382-3BE2842C8812

Q24681784-A6C6078E-D84D-4904-8EEF-53C732C5BAE2

Q24681784-B8433FD2-DD32-4AF7-BA92-99CE3F687B4C

Q24681784-BAAE2A86-A796-4D07-B112-AD80B633357C

Q24681784-DEC52178-7E1D-4B39-8E72-0610601038F2

P2860

Q24681784-1E361F79-641E-4519-8D58-AD183EE8B49E

Q24681784-222A658E-7956-4E6D-AC18-3EEB7927FD3A

Q24681784-604752A4-6477-4AAB-9854-1BB3ADC0B99E

Q24681784-60F66390-F4DF-48CC-9F4F-243C9919CF98

Q24681784-827EBE99-8380-4F0C-9407-0B0102C9D944

Q24681784-8C67E58E-CB42-42EB-B4A8-6BA3CEFC81B0

Q24681784-8E07CFFD-4514-4054-AA0F-D589B9B49D47

Q24681784-9BC23C06-459C-4B3D-82F8-EB5BB5ACDA7C

Q24681784-B0512614-2397-4DD7-9444-DD9E48CA8FA1

Q24681784-B288F7D8-3104-4CFC-A008-3971857DEB48

P304

Q24681784-42DD4277-1BA4-43E8-B847-4C224F7F962D

P31

Q24681784-F1A88E5C-1297-4719-B88D-27AD1149749D

P356

Q24681784-16234CA8-2B4D-4BE9-B759-86A7CE2E391E

P407

Q24681784-3CF2210E-FB99-4404-B90F-CDA6F7EBD465

P433

Q24681784-777F77E0-FF45-41C7-8EEC-3584272EE03E

P478

Q24681784-4294B7F7-2B0E-4757-83B4-466A76E6122F

P577

Q24681784-C7DC81B9-03B8-4318-B8BD-78912B9CBE87

P5875

Q24681784-8B6E5273-D171-4772-82EE-3EEC0AA3D63C

P698

Q24681784-622C7968-A329-4536-99DD-4C4CE44E45ED

P932

Q24681784-BF2AC4E4-999B-433C-97D8-52CE4256A55F

P356

J.1365-2249.1993.TB08223.X

P1433

Clinical and Experimental Immunology

P1476

Studies on the mechanism of co ...... f antibody binding to HIV gp41

@en

P2093

E Ujhelyi

http://www.w3.org/2001/XMLSchema#string

G Arlaud

http://www.w3.org/2001/XMLSchema#string

G Füst

http://www.w3.org/2001/XMLSchema#string

H Hampl

http://www.w3.org/2001/XMLSchema#string

K Nagy

http://www.w3.org/2001/XMLSchema#string

M P Dierich

http://www.w3.org/2001/XMLSchema#string

N M Thielens

http://www.w3.org/2001/XMLSchema#string

T Hidvégi

http://www.w3.org/2001/XMLSchema#string

Z Prohászka

http://www.w3.org/2001/XMLSchema#string

P2860

Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41

Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.

Neutralization of HIV-1: a paradox of humoral proportions.

Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.

Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.

Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro

Differential elution of Clq, Clr and Cls from human Cl bound to immune aggregates. Use in the rapid purification of Cl subcomponents.

HIV and human complement: mechanisms of interaction and biological implication.

Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV.

P304

490-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2249.1993.TB08223.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

1993-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14946102

http://www.w3.org/2001/XMLSchema#string

P698

8252810

http://www.w3.org/2001/XMLSchema#string

P932

1534428

http://www.w3.org/2001/XMLSchema#string